Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Ying Huang, MA, MS, Amy S. Ruppert, MAS, PhD, Farrukh T. Awan, MD MS, Corrinne Hoffman, CNP, Kami J. Maddocks, MD, Mark Reid, CNP, Jennifer A. Woyach, MD, Thomas Whitlow, BA, Jeffrey A. Jones, MD MPH, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 693.

https://doi.org/10.1182/blood-2018-99-114169

Published: 2018

Journal Articles

Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Kami J. Maddocks, MD, Farrukh T. Awan, MD MS, Ying Huang, MA, MS, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MD MS, Samantha Jaglowski, MD MPH, Basem M. William, MRCP, MD, Kristie A. Blum, MD, Beth A. Christian, MD

Blood (2018) 132 (Supplement 1): 4185.

https://doi.org/10.1182/blood-2018-99-117172

Published: 2018

Journal Articles

Home Based Primary Care for Patients with Sickle Cell Disease

Mikaela D Moore, BS, Andrew Schamess, MD, Nita Williams, BS, Ying Huang, MA, MS, Gifty Menka, RN, Payal C Desai, MD

Blood (2018) 132 (Supplement 1): 4721.

https://doi.org/10.1182/blood-2018-99-120040

Published: 2018

Journal Articles

Exercise Is Medicine: Restoring Function in Older Adults with Hematologic Malignancy

Ashley E. Rosko, MD, Sarah A Wall, MD, Carolyn Presley, MD, ReNea Owens, Desiree Jones, Ying Huang, MA, MS, Michelle Naughton, PhD MPH

Blood (2018) 132 (Supplement 1): 4870.

https://doi.org/10.1182/blood-2018-99-120167

Published: 2018

Journal Articles

Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Ying Huang, MA, MS, Amy Stark, MAS, Farrukh T. Awan, MD MS, Kami J. Maddocks, MD, Jennifer A. Woyach, MD, Thomas Whitlow, BA, John C. Byrd, MD, Jeffrey A. Jones, MD MPH, MBA

Blood (2017) 130 (Supplement 1): 431.

https://doi.org/10.1182/blood.V130.Suppl_1.431.431

Published: 2017

Journal Articles

Outcomes of Patients with Primary Refractory Mantle Cell Lymphoma, a Single Center Retrospective Study

David A Bond, MD, Ying Huang, MA, MS, Beth Christian, MD, Kami J. Maddocks, MD

Blood (2017) 130 (Supplement 1): 1503.

https://doi.org/10.1182/blood.V130.Suppl_1.1503.1503

Published: 2017

Journal Articles

Ingle-Institutional Experience with the Use of PD-1 Inhibitors for the Treatment of Richter's Syndrome

Kerry A. Rogers, MD, Ying Huang, MA, MS, Emily Dotson, PharmD, Jordan Lundberg, PharmD, Leslie Andritsos, MD, Farrukh T. Awan, MD MS, Jeffrey A. Jones, MD MPH, MBA, Jennifer A. Woyach, MD, John C. Byrd, MD

Blood (2017) 130 (Supplement 1): 5345.

https://doi.org/10.1182/blood.V130.Suppl_1.5345.5345

Published: 2017

Journal Articles

Toxigenic Clostridium Difficile Colonization in Patients with Hematologic Malignancies Admitted to the Hospital for Chemotherapy or Hematopoietic Cell Transplantation

John L Vaughn, MD, Misty Lamprecht, MS, Ying Huang, MA, MS, Mirela Anghelina, Joan-Miquel Balada-Llasat, PharmD, PhD, Zeinab El Boghdadly, MBBCh, Rachel Childs, Preeti Pancholi, PhD, Leslie A Andritsos, MD

Blood (2017) 130 (Supplement 1): 3211.

https://doi.org/10.1182/blood.V130.Suppl_1.3211.3211

Published: 2017

Journal Articles

a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)

Kami J. Maddocks, MD, Jonathon B. Cohen, MD, Ying Huang, MA, MS, Beth A Christian, MD, Don M Benson, MD PhD, Jeffrey Jones, MD MPH, Christopher Flowers, MD MS, Leonard T. Heffner, MD, Cynthia Jenkins, RN, Jennfer Sexton, MHA, CCRC, Alison Neal, MPH, Melissa Kives, MPH, Kristie A. Blum, MD

Blood (2016) 128 (22): 1776.

https://doi.org/10.1182/blood.V128.22.1776.1776

Published: 2016

Journal Articles

Psychosocial Risk Is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation

Daniel R Richardson, MD, Ying Huang, MA, MS, Patrick Elder, MS, Joanna Newlin, LISW, Cyndi Kirkendall, LISW, Steven M Devine, MD, Leslie A. Andritsos, MD, Don M Benson, MD PhD, William Blum, MD, Yvonne A Efebera, MD MPH, Craig C Hofmeister, Samantha Jaglowski, MD MPH, Rebecca B Klisovic, MD, Heather L McGinty, PhD, Sam Penza, MD, Sumithra Vasu, MBBS, Basem M William, MD, Ashley E Rosko, MD

Blood (2016) 128 (22): 1241.

https://doi.org/10.1182/blood.V128.22.1241.1241

Published: 2016

Journal Articles

Cytomegalovirus Reactivation Does Not Increase Subsequent Risk for Acute Graft-Versus-Host Disease, Malignant Disease Relapse, or Infection Following Allogeneic Hematopoietic Cell Transplantation

Blood (2016) 128 (22): 3409.

https://doi.org/10.1182/blood.V128.22.3409.3409

Published: 2016

Journal Articles

Early Infection Attenuates Hematologic Malignant Disease Relapse Following Initial Allogeneic Hematopoietic Cell Transplantation

Blood (2016) 128 (22): 3410.

https://doi.org/10.1182/blood.V128.22.3410.3410

Published: 2016

Journal Articles

Unexplained Hypoxia and Shunting on Echocardiography in Patients with Sickle Cell Disease: A Retrospective Review

Payal C. Desai, MD, Nicole Kendel, MD, Melanie Heinlein, BS, Ying Huang, MA, MS, Eric H. Kraut, MD, Namita Sood, Subha Raman, MD

Blood (2016) 128 (22): 3673.

https://doi.org/10.1182/blood.V128.22.3673.3673

Published: 2016

Journal Articles

A Retrospective Evaluation of the Impact of Pre-Emptive Plerixafor Administration on Collection Efficiency in Patients with Myeloma Undergoing Stem Cell Mobilization

Leslie A. Andritsos, MD, Ying Huang, MA, MS, Tao Fan, PhD, Keith Huff, PharmD, Ed Drea, PharmD, Ali McBride, PharmD,MS

Blood (2016) 128 (22): 5740.

https://doi.org/10.1182/blood.V128.22.5740.5740

Published: 2016

Journal Articles

A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Galena Salem, MD, Deborah M. Stephens, DO, Leslie A. Andritsos, MD, Farrukh T. Awan, MD MS, John C. Byrd, MD, Joseph M. Flynn, DO, MPH, Kami J. Maddocks, MD, Ying Huang, MA, MS, Amy S. Ruppert, MAS, Jeffrey A. Jones, MD MPH

Blood (2015) 126 (23): 2951.

https://doi.org/10.1182/blood.V126.23.2951.2951

Published: 2015

Journal Articles

Geriatric Assessment Metrics Are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients

Ashley E Rosko, MD, Craig C Hofmeister, MD MPH, Yvonne A Efebera, MD, Don M Benson, MD PhD, Douglas W Sborov, MD MS, Samantha Jaglowski, MD MPH, Steve Devine, MD, Tanya M Wildes, MD MSCI, James Gillahan, Desiree Jones, Ying Huang, MA, MS, Christin E Burd, PhD

Blood (2015) 126 (23): 3200.

https://doi.org/10.1182/blood.V126.23.3200.3200

Published: 2015

Journal Articles

Myocardial Ischemia in Patients with Sickle Cell Disease: A Retrospective Review

Payal C. Desai, MD, Nicole Kendel, MS, Spero R Cataland, MD, Eric H. Kraut, MD, Ying Huang, MA, MS, Subha Raman, MD

Blood (2015) 126 (23): 2189.

https://doi.org/10.1182/blood.V126.23.2189.2189

Published: 2015

Journal Articles

T-Cell p16 INK4A Expression Increases Post-Transplant in Patients with Multiple Myeloma

Ashley E. Rosko, MD, Craig C Hofmeister, MD MPH, Don Benson, MD PhD, Yvonne A Efebera, MD, Ying Huang, MA, MS, Christin Burd, PhD

Blood (2014) 124 (21): 2023.

https://doi.org/10.1182/blood.V124.21.2023.2023

Published: 2014

Journal Articles

Final Results and Follow-up of a Phase I Study of the Fc Engineered CD19 Antibody XmAb®5574 (aka MOR00208) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Jennifer A. Woyach, MD, Farrukh Awan, MD MS, Ian Flinn, Jesus G. Berdeja, MD, Elizabeth A Wiley, Sharmeen Mansoor, Ying Huang, MA, MS, Gerard Lozanski, MD, Paul A. Foster, MD, John C. Byrd, MD

Blood (2014) 124 (21): 1993.

https://doi.org/10.1182/blood.V124.21.1993.1993

Published: 2014

NARROW

Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia

Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Home Based Primary Care for Patients with Sickle Cell Disease

Exercise Is Medicine: Restoring Function in Older Adults with Hematologic Malignancy

Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Outcomes of Patients with Primary Refractory Mantle Cell Lymphoma, a Single Center Retrospective Study

Ingle-Institutional Experience with the Use of PD-1 Inhibitors for the Treatment of Richter's Syndrome

Toxigenic Clostridium Difficile Colonization in Patients with Hematologic Malignancies Admitted to the Hospital for Chemotherapy or Hematopoietic Cell Transplantation

a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)

Psychosocial Risk Is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation

Cytomegalovirus Reactivation Does Not Increase Subsequent Risk for Acute Graft-Versus-Host Disease, Malignant Disease Relapse, or Infection Following Allogeneic Hematopoietic Cell Transplantation

Early Infection Attenuates Hematologic Malignant Disease Relapse Following Initial Allogeneic Hematopoietic Cell Transplantation

Unexplained Hypoxia and Shunting on Echocardiography in Patients with Sickle Cell Disease: A Retrospective Review

A Retrospective Evaluation of the Impact of Pre-Emptive Plerixafor Administration on Collection Efficiency in Patients with Myeloma Undergoing Stem Cell Mobilization

A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia

Geriatric Assessment Metrics Are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients

Myocardial Ischemia in Patients with Sickle Cell Disease: A Retrospective Review

T-Cell p16 INK4A Expression Increases Post-Transplant in Patients with Multiple Myeloma

Final Results and Follow-up of a Phase I Study of the Fc Engineered CD19 Antibody XmAb®5574 (aka MOR00208) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only